Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

NSCLC Clinical Trial

Official title:

An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01963195
• Other study ID #: DEI-ADNSCLC
• Status: Recruiting
• Phase: Phase 2
• First received: January 4, 2012
• Last updated: May 3, 2017
• Start date: February 2014
• Est. completion date: December 2019

Study information

• Verified date: May 2017
• Source: Anhui Medical University
• Contact: Hu Liu, MD
• Phone: 865512922987
• Email: drliuhu[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of dose escalation of Icotinib in advanced non small cell lung cancer (NSCLC) patients after the therapy of Icotinib, Iressa and Tarceva.

Description:

• 1:to evaluate the efficacy correlation between the tyrosine kinase inhibitor (TKI) drugs and high-dose Icotonib group in advanced NSCLC patients with high -dose Icotinib going on after the routine TKI therapy

• 2 to evaluate the efficacy correlation between different high-dose group in advanced NSCLC patients with high -dose Icotinib going on after the routine TKI therapy

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. NSCLC patients were confirmed by histology or cytology

2. The time interval must be over 4 weeks from previous chemotherapy to registration to participate in this experiment if he or she received chemotherapy,and also have any toxicity to recover.

3. at least one measureable lesion accord to RECIST 1.1 criteria and the lesion accepted no radiotherapy.

• 1 at least one measureable lesion .if only one measureable lesion, the biological nature must be confirmed by cytology or histology.

• 2 a single diameter of lesion could be measured by at least one of the following methods: Chest or abdominal computed tomography(CT)or magnetic resonance imaging(MRI),conventional methods of diameter at least 20mm diameter spiral CT OR at least 10mm.

4. ECOG 0-2 score

5. at least 12 weeks of expected survival time

6. Women of childbearing age must have a pregnancy test 7 days before treatment and the result were negative ,men of childbearing age: surgical sterilization or treatment during and after the end of three months to take contraceptive measures

7. understand and sign a written informed consent voluntarily.

Exclusion Criteria:

If the subject meet any of the following exclusion criteria ,he is no eligible to participate in this study,

1. Before enrollment in this trial have used Erbitux, Herceptin and carried out anti-cancer therapy.

2. use of phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort when take this trial

3. severe allergies to Icotinib

Related Conditions & MeSH terms

• NSCLC

Intervention

Drug:
• Icotinib
Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months

Locations

Country	Name	City	State
China	Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity	Hefei	Anhui

Sponsors (1)

Lead Sponsor	Collaborator
Anhui Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety and efficacy	The efficacy of dose escalation of Icotinib in advanced NSCLC patients after failure of TKI (Icotinib 125mg po tid. Iressa 250mg po qd. Tarceva 150mg po qd) therapy will be evaluated according to the revised RECIST 1.1 (Response Evaluation Criteria In Solid Tumors).; The safety of high dosage of Icotinib will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.	2 years